Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer
详细信息 查看全文
- 作者：Edurne Arriola ; Socorro Maria Rodriguez-Pinilla ; Maryou B. K. Lambros ; Robin L. Jones ; Michelle James ; Kay Savage ; Ian E. Smith ; Mitch Dowsett and Jorge S. Reis-Filho
- 关键词：Anthracyclines ; Breast cancer ; Chromogenic in situ hubridisation ; HER2 ; Topoisomerase II alpha
- 刊名：Breast Cancer Research and Treatment
- 出版年：2007
- 出版时间：December, 2007
- 年：2007
- 卷：106
- 期：2
- 页码：181-189
- 全文大小：320 KB
- 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Oncology - 出版者：Springer Netherlands
- ISSN：1573-7217
文摘
Background TOP2A gene encodes topoisomerase II alpha, the direct molecular target of anthracyclines. This gene is frequently coamplified with HER2. The aims of this study were to analyse the pattern of TOP2A amplification and protein expression in relation to the molecular subgroups of breast cancers; and to define the impact of TOP2A amplification on the outcome of a series of patients homogeneously treated with adjuvant anthracyclines.